Ideas to action: independent research for global prosperity
Search
Filters:
Experts
Facet Toggle
Topics
Facet Toggle
Content Type
Facet Toggle
Publication Type
Facet Toggle
Time Frame
Facet Toggle
Blog Post
December 07, 2022
How exactly should China's policymakers wade through competing models and guidance as it looks to ease its anti-COVID measures? This blog looks at how they should use models, using the case of the state of Hawaii; in sum, recommending that China’s National Health Commission take a thoughtful approac...
POLICY PAPERS
November 28, 2022
The experience of the COVID-19 pandemic—in the US and around the world—highlights the potential feasibility and importance of biomedical R&D for global health and welfare. Drawing from this experience and momentum, this paper argues that the US should deepen its engagement and ambition in global hea...
Blog Post
November 28, 2022
Building on the success of Operation Warp Speed, the US should deepen its engagement and ambition in global health R&D to drive transformative improvements in global health outcomes and security. Specifically, it should consider a subscription model for new antimicrobials; an advance market commitme...
Blog Post
November 17, 2022
How does public health surveillance work, and how can it be done better? Amanda Glassman tackles these questions with Dr. Oliver Morgan of the WHO and Dr. Theo Vos of the Institute for Health Metrics and Evaluation. Together, they examine the successes and limitations of public health surveillance d...
Blog Post
November 16, 2022
How can we produce evidence that is more relevant and useful to policy and practice? This blog explores the main themes of the inaugural conference of Transforming Evidence Network (sessions were organized around making, mobilizing, and using evidence), and reflects on areas for further action, draw...
POLICY PAPERS
November 15, 2022
Antimicrobial drugs form the backbone of modern medicine. Yet over time, use of these drugs selects for mutations that survive exposure to those same drugs, driving “antimicrobial resistance,” or AMR. In the absence of sufficient R&D investment for new antimicrobials, deaths from drug-resistant infe...
Blog Post
October 13, 2022
On this episode of Pandemic Proof, Dr. Ayoade Alakija, the World Health Organization’s Special Envoy for the Access to COVID-19 Tools Accelerator (ACT-A) and co-chair of the African Union’s African Vaccine Delivery Alliance, joins Javier Guzman to discuss global cooperation during health emergencies...
Blog Post
October 06, 2022
Despite alleged “lessons learned” from the COVID-19 pandemic about the need for early containment, getting the messaging right, and a swift rollout of diagnostics, vaccines, and therapeutics, we have seen the same blunders yet again in the monkeypox response, highlighting the inequities in the syste...